Amprenavir
Side effects
Options:
Hide MedDRA Preferred Terms
MedDRA Preferred Term
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
6
|
Hyperglycaemia
|
Hyperglycaemia
|
uncommon, 41% - 58%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Hypertriglyceridaemia
|
Hypertriglyceridaemia
|
common, 40% - 56%
|
|
|
|
|
x
|
x
|
x
|
Blood triglycerides increased
|
Hypertriglyceridaemia
|
common, 40% - 56%
|
|
|
|
|
x
|
x
|
x
|
Diarrhoea
|
Loose stools
|
common, 32% - 60%
|
|
|
|
|
x
|
x
|
x
|
Diarrhoea
|
very common, 5% - 60%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Flatulence
|
Flatulence
|
very common
|
|
|
|
|
|
|
x
|
Inflammation
|
Inflammation
|
very common
|
|
|
|
|
|
|
x
|
Opportunistic infection
|
Opportunistic infection
|
very common
|
|
|
|
|
|
|
x
|
Vomiting
|
Vomiting
|
very common, 2% - 24%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Hypercholesterolaemia
|
Hypercholesterolaemia
|
postmarketing — 9% - 15%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Paraesthesia
|
Paraesthesia
|
1% - 31%
|
|
|
|
|
x
|
x
|
|
Dermatitis
|
Rash
|
very common, 2% - 20%
|
|
x
|
|
x
|
x
|
x
|
x
|
Rash
|
Rash
|
very common, 2% - 20%
|
|
x
|
|
x
|
x
|
x
|
x
|
Affective disorder
|
Affective disorder
|
common, 4% - 13%
|
|
|
|
|
x
|
x
|
x
|
Decreased appetite
|
Anorexia
|
common
|
|
|
|
|
|
|
x
|
Depression
|
Depressive disorder
|
common
|
|
|
|
|
|
|
x
|
Dysthymic disorder
|
Depressive disorder
|
common
|
|
|
|
|
|
|
x
|
Gastrointestinal disorder
|
Gastrointestinal disorder
|
common
|
|
|
|
|
|
|
x
|
Gastrointestinal symptom NOS
|
|
|
|
|
|
|
|
x
|
Nausea
|
Nausea
|
very common, 4% - 7%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Tremor
|
Tremor
|
common
|
|
|
|
|
|
|
x
|
Amylase increased
|
Amylase increased
|
common
|
|
|
|
|
|
|
x
|
Abdominal discomfort
|
Abdominal discomfort
|
common
|
|
|
|
|
|
|
x
|
Hepatobiliary disease
|
Hepatobiliary disease
|
common
|
|
|
|
|
|
|
x
|
Sleep disorder
|
Sleep disorder
|
common
|
|
|
|
|
|
|
x
|
Fat redistribution
|
Fat redistribution
|
common
|
|
|
|
|
|
x
|
x
|
Paraesthesia oral
|
Perioral paraesthesia
|
common
|
|
|
|
|
|
|
x
|
Paraesthesia oral
|
postmarketing
|
|
x
|
x
|
x
|
|
|
|
Headache
|
Headache
|
very common, 2% - 4%
|
|
x
|
x
|
x
|
|
x
|
x
|
Transaminases increased
|
Transaminases increased
|
uncommon, common
|
|
|
|
|
|
|
x
|
Asthenia
|
Fatigue
|
very common, 1% - 2%
|
|
x
|
x
|
x
|
|
x
|
x
|
Fatigue
|
Fatigue
|
very common, 1% - 2%
|
|
x
|
x
|
x
|
|
x
|
x
|
Abdominal pain
|
Abdominal pain
|
common, 0% - 2%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Gastrointestinal pain
|
Abdominal pain
|
common, 0% - 2%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Hyperbilirubinaemia
|
Hyperbilirubinaemia
|
uncommon
|
|
|
|
|
|
|
x
|
Angioedema
|
Angioedema
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
|
|
x
|
Cardiac disorder
|
Cardiac disorder
|
postmarketing
|
|
x
|
x
|
x
|
|
|
|
Myocardial infarction
|
Myocardial infarction
|
postmarketing
|
|
x
|
x
|
x
|
|
|
|
Acute coronary syndrome
|
Myocardial infarction
|
postmarketing
|
|
x
|
x
|
x
|
|
|
|
Nervous system disorder
|
Nervous system disorder
|
postmarketing, common
|
|
x
|
x
|
x
|
|
|
x
|
Erythema multiforme
|
Stevens-Johnson syndrome
|
rare
|
|
|
|
|
x
|
x
|
x
|
Stevens-Johnson syndrome
|
Stevens-Johnson syndrome
|
rare
|
|
|
|
|
x
|
x
|
x
|
Malnutrition
|
Malnutrition
|
postmarketing
|
|
x
|
x
|
x
|
|
|
x
|
Skin disorder
|
Unspecified disorder of skin and subcutaneous tissue
|
postmarketing
|
|
x
|
x
|
x
|
|
|
x
|
Nephrolithiasis
|
Nephrolithiasis
|
postmarketing
|
|
x
|
x
|
x
|
|
|
|
Mental disorder
|
Mental disorder
|
|
|
|
|
|
|
|
x
|
Connective tissue disorder
|
Connective tissue disorder
|
|
|
|
|
|
|
|
x
|
Diabetes mellitus
|
Diabetes mellitus
|
|
|
|
|
|
x
|
x
|
|
Hepatitis B
|
Hepatitis B
|
|
|
|
|
|
|
|
x
|
Breast enlargement
|
Hypertrophy of breast
|
|
|
|
|
|
|
|
x
|
Insulin resistance
|
Insulin resistance
|
|
|
|
|
|
|
|
x
|
Lipodystrophy acquired
|
Lipodystrophy
|
|
|
|
|
|
|
|
x
|
Myositis
|
Myositis
|
|
|
|
|
|
|
|
x
|
Neutropenia
|
Neutropenia
|
|
|
|
x
|
x
|
|
|
|
Pruritus
|
Pruritus
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Rhabdomyolysis
|
Rhabdomyolysis
|
|
|
|
|
|
|
|
x
|
Blood creatine phosphokinase increased
|
Creatine phosphokinase increased
|
|
|
|
|
|
|
|
x
|
Liver function test abnormal
|
Liver function test abnormal
|
|
|
|
|
|
|
|
x
|
Aspartate aminotransferase increased
|
Aspartate aminotransferase increased
|
|
|
x
|
x
|
x
|
|
|
|
Alanine aminotransferase increased
|
Alanine aminotransferase increased
|
|
|
x
|
x
|
x
|
|
|
|
Myalgia
|
Myalgia
|
|
|
|
|
|
|
|
x
|
Musculoskeletal discomfort
|
Myalgia
|
|
|
|
|
|
|
|
x
|
Discomfort
|
Discomfort
|
|
|
|
|
|
|
x
|
|
Lipohypertrophy
|
Buffalo hump
|
|
|
|
|
|
x
|
x
|
x
|
Abdominal symptom
|
Abdominal symptom
|
|
|
|
|
|
|
x
|
|
Hyperlactacidaemia
|
Hyperlactacidaemia
|
|
|
|
|
|
|
|
x
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 20 |
Source: | FDA Structured Product Label |
---|
Side effects: | 20 |
Source: | FDA Structured Product Label |
---|
Side effects: | 21 |
Source: | FDA Structured Product Label |
---|
Side effects: | 16 |
Source: | FDA |
---|
Side effects: | 21 |
Source: | FDA |
---|
Side effects: | 48 |
Source: | EMA |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|